Biosimilars: Friend or foe to healthcare?
Our article in Pharma Market Europe and our Free Thinking white paper looks at the opportunities for biosimilars and the threats to innovator biologics.
Biologics, whose active substance is derived from a living organism, have enabled healthcare to make significant therapeutic advances across a whole raft of therapy areas since their introduction in the 1970s. However, these medicines come at a price, reflecting the complexities involved in developing and manufacturing products derived from living cells. Annual treatment costs in the US can range from US$25,000 to US$200,000.
Biosimilars medicines, the follow-on “generics” to biologics which have come off-patent, present a significant opportunity to introduce cutting-edge therapies to the treatment landscape for many diseases, while also addressing the cost-effectiveness demands now being made on global healthcare systems.
The article considers how the European landscape for biosimilars is ripe for transformation as more mAbs or anti-TNFs (Tumour Necrosis Factors) for inflammatory conditions such as rheumatoid arthritis enter the fray. Referencing data from Research Partnership's Therapy Watch syndicated study in RA, and gathering opinion from a leading UK payer and French physician, the article highlights that awareness of biosimilars is currently very low and there are concerns over quality and safety, so biosimilars still face certain challenges if they are to achieve sufficient uptake.
Download the PME article now
Full white paper available on request. Click here to request your copy.